Artialis

Executive Summary

Artialis is a Belgian Contract Research and Development Organization (CRDO) founded in 2014, specializing in end-to-end R&D services for products targeting healthy aging. The company focuses on age-related musculoskeletal and neurodegenerative diseases, offering biotesting, preclinical, and clinical services to clients ranging from early research through market entry. Operating as a private, preclinical-stage entity, Artialis positions itself as a development partner rather than a drug developer, mitigating direct therapeutic risk. Its expertise in aging-related indications aligns with growing market demand for longevity and geroscience solutions. While the company has a clear niche and service model, its private status and limited public disclosures constrain visibility into financial performance and pipeline progress. Nonetheless, its role in enabling client programs could yield indirect catalysts through partnerships or client milestones.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership with a Biotechnology Company70% success
• Q3 2026Launch of Preclinical Service Platform for Neurodegenerative Diseases60% success